HIV

Showing 15 posts of 200 posts found.

J&J announce promising Phase 1/2a results for HIV vaccine

October 23, 2018
Manufacturing and Production AIDS, HIV, J&J, JJ, Vaccine, infectious diseases

The world may be one step closer to discovering a preventative vaccine for HIV following American multinational Johnson & Johnson’s …

1920px-hiv-budding-color

Researchers launch Phase 1 trial of HIV vaccine

October 18, 2018
Research and Development AIDS, HIV, Vaccine, infection, resdearch

Researchers working with the non-profit organisation the International AIDS Vaccine Initiative (IAVI) have announced the launch of a Phase I …

nhs_sign

NHS England to fund availability of Janssen’s single tablet HIV combo Symtuza

October 1, 2018
Sales and Marketing HIV, Janssen, NHS, Symtuza, pharma

Great news for HIV patients in the UK as Janssen reveals that NHS England will provide critical funding for its …

800px-t_lymphocyte_16760076824

Antibody therapy supresses HIV for months after treatment, study shows

October 1, 2018
Sales and Marketing HIV, immunology, immunotherapy, nature, research

Researchers from the New York City based Rockefeller University have developed a novel immunotherapy, which is capable of suppressing HIV …

6813384933_1fb31d73fb_z

HIV on the rise among straight men in Australia

September 24, 2018
Medical Communications, Sales and Marketing AIDS, Aboriginal, Australia, HIV, Kirby Institute

The number of new HIV diagnoses is on the rise among heterosexual men in Australia, according to a new report …

6813384933_1fb31d73fb_z

Ibalisumab effective in in treating multidrug resistant HIV

August 16, 2018
Research and Development AIDS, HIV, multidrug resistance, phase 3

The monoclonal antibody Ibalizumab has shown significant antiviral activity against multidrug resistant HIV infections, according to the results of a …

Janssen and ViiV’s monthly injectable HIV combo proves non-inferior to daily standard of care

August 15, 2018
Research and Development HIV, Janssen, ViiV Healthcare, pharma

Janssen and GSK’s ViiV Healthcare have unveiled strong new Phase 3 data on its two-drug regimen, injected once a month, …

32514377531_3583dbc34b_z

Those at risk of HIV to be offered PrEP drugs in England and Northern Ireland

July 27, 2018
Medical Communications AIDS, England, HIV, PrEP, Terrence Higgins Trust

Those at risk of contracting HIV will now be offered PrEP drugs in England and Northern Ireland through a programme …

janssen_latest_logo_on_sign

Janssen’s Symtuza scores approval with the FDA in HIV-1

July 18, 2018
Sales and Marketing HIV, Janssen, Symtuza, pharma

Janssen has announced that Symtuza (D/C/F/TAF) has received approval from the FDA in the treatment of human immunodeficiency virus type …

640px-hiv-budding-color

Abivax drug lowers HIV DNA in blood and tissue, but has the opposite effect for some

July 4, 2018
Research and Development Abivax, HIV, pharma

Biotechnology firm Abivax has lifted the curtain on new Phase 2a data for its HIV therapy ABX464, showing that the …

gilead-sciences

European Commission greenlights Gilead’s Biktarvy for HIV-1

June 25, 2018
Sales and Marketing Biktarvy, EU, Europe, European Commission, HIV, HIV-1, pharma

Good news for Gilead and HIV patients across the European Union today as the prominent pharma firm announced that its …

Insider Interview: Gilead’s fight against HIV comes into bloom

May 30, 2018
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Gilead, HIV, Insider Interview, pharma

Mike Elliott, Vice President of Medical Affairs at Gilead (pictured, right), chats about the company’s sponsorship of a ‘A life …

640px-hiv-budding-color

India, Sweden and The Netherlands form HIV/AIDS research partnership

May 22, 2018
Manufacturing and Production, Research and Development AIDS, HIV, India, Sweden, The Netherlands, pharma

A first-of-its-kind collaboration has been announced by the governments of India, Sweden and The Netherlands with the goal of advancing …

The Gateway to Local Adoption Series

Latest content



Pace appoints Ken Beyer as CEO

December 10, 2025